Get the Agenus Stock Quote: Financial Data and Analyst Forecast

Author

Reads 801

Close-up shot of various pharmaceutical pills, capsules, and medication bottles on a table.
Credit: pexels.com, Close-up shot of various pharmaceutical pills, capsules, and medication bottles on a table.

To get the Agenus stock quote, you'll want to check the company's financial data, which is publicly available. Agenus is a biopharmaceutical company that develops cancer immunotherapy products.

Their financial data can be found on reputable websites such as Yahoo Finance or Google Finance. These websites provide up-to-date information on the company's revenue, expenses, and net income.

Agenus has reported significant revenue growth in recent years, with a notable increase in 2020. According to their financial reports, the company's revenue jumped from $30 million to $150 million.

Analysts also provide forecasts for Agenus' future financial performance. These forecasts can be found on websites like Seeking Alpha or Thomson Reuters.

If this caught your attention, see: S B I Card Share Price

A unique perspective: Enersys Stock Quote

Financial Data

Agenus's financial performance in 2023 was impressive, with revenue increasing by 59.47% to $156.31 million.

Their revenue has continued to grow, reaching $160.427 million in the trailing twelve months (TTM). This is a significant increase, indicating the company's financial health.

One notable aspect of Agenus's financials is their volatility, with a 3-Year Sharpe Ratio of -1.24 and a 3-Year Sortino Ratio of -1.34. This suggests that the company's stock price has been quite volatile over the past few years.

Here's a summary of Agenus's key financial statistics:

Their losses were also substantial, at -$245.97 million, which is 11.7% more than in 2022.

Financial Performance

Credit: youtube.com, FINANCIAL STATEMENTS: all the basics in 8 MINS!

Agenus's financial performance in 2023 was impressive, with revenue reaching $156.31 million, a 59.47% increase from the previous year.

This significant growth in revenue is a testament to the company's strong business model and ability to adapt to changing market conditions.

Agenus's losses in 2023 were -$245.97 million, an 11.7% increase from the previous year. This may seem concerning, but it's essential to consider the company's revenue growth and potential for future profitability.

Here are some key financial metrics for Agenus:

Keep in mind that these metrics should be considered in the context of the company's overall financial performance and industry trends.

Investor Insights

As an investor, it's essential to understand the company's financial health, and Agenus stock quote provides a glimpse into this. The company's revenue has been steadily increasing, reaching $143.8 million in 2020.

Agenus has a strong pipeline of clinical-stage programs, with several candidates in Phase 1 and Phase 2 trials. This suggests a promising future for the company's growth.

Analyst Forecast

Credit: youtube.com, Analyst Estimates for Stocks: Everything You Need to Know!

According to analyst forecasts, AGEN stock is looking up, with an average rating of "Buy" from 3 experts.

The 12-month stock price forecast is a whopping $10.5, representing a 194.94% increase from the latest price.

Average Brokerage Rating

The Average Brokerage Rating is a key metric that can give you an idea of how analysts and brokers feel about a particular stock. It's calculated based on the actual recommendations made by brokerage firms.

Agenus currently has an average brokerage recommendation (ABR) of 2.60 on a scale of 1 to 5, with 1 being a Strong Buy and 5 being a Strong Sell. This ABR is the same as it was a month ago, based on five recommendations.

One of the five recommendations is a Strong Buy, which represents 20% of all recommendations. This is consistent with the recommendation from a month ago.

Here's a breakdown of the current ABR:

Keep in mind that the ABR is just one piece of the puzzle when it comes to making investment decisions. It's essential to consider multiple factors and do your own research before making a move.

Frequently Asked Questions

Is Agenus a good stock to buy?

Agenus has a Moderate Buy rating with a price target of $8.50, indicating potential growth but also some caution. If you're considering buying Agenus stock, it's worth exploring the latest analyst opinions and market trends for a more informed decision.

Who owns Agenus stock?

Agenus stock is primarily owned by institutional investors, including Vanguard Group Inc, BlackRock, Inc., and State Street Corp, among others. These large shareholders hold significant stakes in the company, influencing its direction and performance.

Caroline Cruickshank

Senior Writer

Caroline Cruickshank is a skilled writer with a diverse portfolio of articles across various categories. Her expertise spans topics such as living individuals, business leaders, and notable figures in the venture capital industry. With a keen eye for detail and a passion for storytelling, Caroline crafts engaging and informative content that captivates her readers.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.